# A Phase I Trial of a LTK63 Adjuvated Tuberculosis Nasal Subunit Vaccine (Ag85B-ESAT6)

> **NCT00440544** · PHASE1 · TERMINATED · sponsor: **St George's, University of London** · enrollment: 9 (actual)

## Conditions studied

- Tuberculosis

## Interventions

- **BIOLOGICAL:** Ag85B-ESAT6 fusion protein H1
- **BIOLOGICAL:** Ag85B-ESAT6 fusion protein H1
- **BIOLOGICAL:** Ag85B-ESAT6 fusion protein H1
- **BIOLOGICAL:** Ag85B-ESAT6 fusion protein H1
- **BIOLOGICAL:** Ag85B-ESAT6 fusion protein H1
- **BIOLOGICAL:** Ag85B-ESAT6 fusion protein H1

## Key facts

- **NCT ID:** NCT00440544
- **Lead sponsor:** St George's, University of London
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-01
- **Primary completion:** 2007-11
- **Final completion:** 2008-02
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Safety Issues
- **Last updated:** 2008-11-03

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00440544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00440544, "A Phase I Trial of a LTK63 Adjuvated Tuberculosis Nasal Subunit Vaccine (Ag85B-ESAT6)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00440544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*